InCube Ventures

Tasso, Inc. is a Seattle-based company founded in 2012 that specializes in manufacturing blood sample collection devices designed for patient convenience. The company's innovative devices enable individuals to collect their own blood samples safely and easily at home, eliminating the need for clinic visits. These disposable, compact devices feature interchangeable cartridges that ensure proper blood preparation immediately upon sample collection. By allowing patients to manage their blood sampling process, Tasso aims to streamline blood-based diagnostics and enhance the overall experience of medical testing.

Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies aimed at addressing unmet medical needs for patients globally. The company's flagship technology, known as Electrical Nerve Block, targets chronic pain conditions, including neuroma and residual limb pain, chronic post-surgical pain, and chronic migraine. Neuros Medical also offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and associated external devices. Established in 2008, the company is dedicated to advancing innovative solutions for pain management.

Metagenomi, Inc. is a biotechnology company focused on developing gene editing systems aimed at treating genetic diseases. Founded in 2016 and based in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to uncover novel genome editing technologies derived from previously uncharacterized organisms. The company's innovative discovery platform enables the creation of highly efficient and specific gene editing tools, including programmable nucleases, base editors, and advanced integration systems such as prime editing and CRISPR-associated transposases. By harnessing these naturally evolved systems, Metagenomi seeks to address a wide range of genetic mutations that traditional genome engineering approaches have struggled to target, with the ultimate goal of providing transformative therapies for patients globally.

Neptune Medical is a venture capital-funded start-up focused on developing, manufacturing, and commercializing single-use medical devices specifically for gastroenterology. The company creates innovative devices aimed at enhancing patient outcomes and increasing the safety and precision of minimally invasive procedures. Their proprietary technology allows for superior tip control, enabling the endoscope to maneuver effectively in various anatomies while maintaining an open lumen to facilitate scope swapping and re-insertion without complications. This design improves the efficiency of procedures, reduces anesthesia time, and enhances patient comfort, making Neptune Medical's products valuable assets in both gastroenterology and broader endoscopic applications.

Metagenomi, Inc. is a biotechnology company focused on developing gene editing systems aimed at treating genetic diseases. Founded in 2016 and based in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to uncover novel genome editing technologies derived from previously uncharacterized organisms. The company's innovative discovery platform enables the creation of highly efficient and specific gene editing tools, including programmable nucleases, base editors, and advanced integration systems such as prime editing and CRISPR-associated transposases. By harnessing these naturally evolved systems, Metagenomi seeks to address a wide range of genetic mutations that traditional genome engineering approaches have struggled to target, with the ultimate goal of providing transformative therapies for patients globally.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.

Metagenomi, Inc. is a biotechnology company focused on developing gene editing systems aimed at treating genetic diseases. Founded in 2016 and based in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to uncover novel genome editing technologies derived from previously uncharacterized organisms. The company's innovative discovery platform enables the creation of highly efficient and specific gene editing tools, including programmable nucleases, base editors, and advanced integration systems such as prime editing and CRISPR-associated transposases. By harnessing these naturally evolved systems, Metagenomi seeks to address a wide range of genetic mutations that traditional genome engineering approaches have struggled to target, with the ultimate goal of providing transformative therapies for patients globally.

WhiteSwell Limited is a Galway-based company focused on advancing the treatment of acute decompensated heart failure (ADHF), a condition that leads to significant hospitalizations and emergency room visits. Founded in 2014, WhiteSwell has developed a unique catheter-based medical device that targets the lymphatic system, enabling the removal of excess fluid from both interstitial and intravascular spaces without compromising renal function. By creating a low-pressure zone at the thoracic duct outlet, the device reduces resistance to lymphatic drainage, thereby improving clinical outcomes for patients suffering from this serious condition. The company also has offices in Shefayim, Israel, and Palo Alto, California, emphasizing its commitment to addressing the critical need for effective and safe treatment options for ADHF, which is associated with high mortality rates.

Fe3 Medical, Inc., operating as Bria Medical, specializes in developing transdermal therapies aimed at treating iron deficiency anemia. The company has created a disposable transdermal patch that delivers around 10 milligrams of iron directly through the skin, effectively bypassing the gastrointestinal tract and minimizing side effects commonly associated with oral iron supplements. Primarily targeting women, Fe3 Medical focuses on providing a safe and non-toxic solution for individuals suffering from this condition. Established in 2008, the company is headquartered in San Antonio, Texas.

Rani Therapeutics, LLC is a clinical-stage biotherapeutics company that focuses on the development of oral delivery technologies for large drug molecules, such as peptides, proteins, and antibodies. The company has created the RaniPill capsule, a proprietary and patented platform designed to administer biologics orally, offering a convenient alternative to traditional subcutaneous or intravenous injections. This capsule is engineered to deliver precise therapeutic doses upon reaching the small intestine. Rani Therapeutics is advancing various treatments, including TNFa inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, their portfolio includes therapies for multiple sclerosis, type II diabetes, and various inflammatory diseases. Founded in 2012 and based in San Jose, California, Rani Therapeutics has conducted several preclinical and clinical studies to assess the safety and effectiveness of its technologies, building a robust intellectual property portfolio in the process.

Channel Medsystems, Inc. is a medical device company focused on women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in developing cryothermic technology that integrates cryothermic energy into a user-friendly, handheld device. This innovative delivery system allows for effective endometrial cryoablation without the need for separate control units or extensive capital equipment, making it more accessible for patients and healthcare providers. Channel Medsystems aims to empower women to take control of their health by providing cutting-edge solutions that enhance their healthcare experience.

PLEXUSS is an education technology company that connects students with a variety of post-secondary educational opportunities through its innovative platform. By utilizing a Global Student Network, PLEXUSS helps millions of students access life-changing educational resources on a daily basis. The platform employs advanced matching algorithms, big data analytics, and machine learning to facilitate connections between students and the most compatible colleges, as well as to provide access to valuable resources such as alumni networks, majors, scholarships, and professional college counseling. This comprehensive approach aims to simplify the college recruitment process and support students in finding their ideal educational paths.

Rani Therapeutics, LLC is a clinical-stage biotherapeutics company that focuses on the development of oral delivery technologies for large drug molecules, such as peptides, proteins, and antibodies. The company has created the RaniPill capsule, a proprietary and patented platform designed to administer biologics orally, offering a convenient alternative to traditional subcutaneous or intravenous injections. This capsule is engineered to deliver precise therapeutic doses upon reaching the small intestine. Rani Therapeutics is advancing various treatments, including TNFa inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, their portfolio includes therapies for multiple sclerosis, type II diabetes, and various inflammatory diseases. Founded in 2012 and based in San Jose, California, Rani Therapeutics has conducted several preclinical and clinical studies to assess the safety and effectiveness of its technologies, building a robust intellectual property portfolio in the process.

Rani Therapeutics, LLC is a clinical-stage biotherapeutics company that focuses on the development of oral delivery technologies for large drug molecules, such as peptides, proteins, and antibodies. The company has created the RaniPill capsule, a proprietary and patented platform designed to administer biologics orally, offering a convenient alternative to traditional subcutaneous or intravenous injections. This capsule is engineered to deliver precise therapeutic doses upon reaching the small intestine. Rani Therapeutics is advancing various treatments, including TNFa inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, their portfolio includes therapies for multiple sclerosis, type II diabetes, and various inflammatory diseases. Founded in 2012 and based in San Jose, California, Rani Therapeutics has conducted several preclinical and clinical studies to assess the safety and effectiveness of its technologies, building a robust intellectual property portfolio in the process.

Channel Medsystems, Inc. is a medical device company focused on women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in developing cryothermic technology that integrates cryothermic energy into a user-friendly, handheld device. This innovative delivery system allows for effective endometrial cryoablation without the need for separate control units or extensive capital equipment, making it more accessible for patients and healthcare providers. Channel Medsystems aims to empower women to take control of their health by providing cutting-edge solutions that enhance their healthcare experience.

BodyMedia, founded in 1999 and based in Pittsburgh, PA, specializes in wearable body monitoring devices that gather physiological data to enhance health, wellness, and fitness. The company offers a range of continuous on-body monitors that utilize proprietary technology validated for clinical accuracy. These devices serve both consumers and health professionals, facilitating behavioral adjustments aimed at weight management and active living—critical factors in addressing serious health issues. BodyMedia's products include a calorie management system that tracks calories burned against those consumed, alongside body monitoring systems that record various physiological metrics analyzed through its SenseWear software. The company has contributed significantly to health research, participating in over 100 clinical studies related to obesity, diabetes, and other medical conditions, thereby creating one of the largest databases of human physiological information.

IntraPace, Inc. specializes in the development and marketing of implantable devices aimed at treating obesity. Founded in 2001 and located in Mountain View, California, the company has created the abiliti system, which stimulates a satiety response to facilitate weight loss. This innovative device is based on technology commonly used in cardiac pacemakers and defibrillators, allowing for implantation through standard laparoscopic methods. Notably, the abiliti system does not alter the digestive system's anatomy and imposes no restrictions on a patient's dietary intake, making it a versatile option for individuals seeking weight management solutions.

Spinal Modulation, Inc., based in Menlo Park, California, specializes in the research and development of medical devices aimed at treating chronic pain. With a significant portion of the adult population affected by severe chronic pain and limited treatment options available, the company addresses this critical healthcare challenge through its Axium Neurostimulator System. This next-generation intraspinal neuromodulation therapy specifically targets the dorsal root ganglion (DRG) to deliver electrical pulses that disrupt pain signals before they reach the brain. The system has demonstrated effectiveness in managing chronic intractable leg pain and other complex pain areas, such as the back and foot, providing a tailored approach for pain relief. By allowing adjustments to focus on either broad or specific pain areas, Spinal Modulation's technology aims to enhance patient comfort and reduce the adverse effects commonly associated with traditional spinal cord stimulators.

Sonoma Orthopedics specializes in the design and development of proprietary orthopedic implants aimed at addressing complex fractures. Utilizing the WaviBody technology platform, the company provides quick and minimally invasive surgical solutions tailored for active patients. Their focus is on fracture fixation devices that enable orthopedic surgeons to effectively repair challenging bone geometries. By offering operative treatments that facilitate faster recovery, Sonoma Orthopedics aims to help patients return to work and their daily activities sooner.

Spinal Modulation, Inc., based in Menlo Park, California, specializes in the research and development of medical devices aimed at treating chronic pain. With a significant portion of the adult population affected by severe chronic pain and limited treatment options available, the company addresses this critical healthcare challenge through its Axium Neurostimulator System. This next-generation intraspinal neuromodulation therapy specifically targets the dorsal root ganglion (DRG) to deliver electrical pulses that disrupt pain signals before they reach the brain. The system has demonstrated effectiveness in managing chronic intractable leg pain and other complex pain areas, such as the back and foot, providing a tailored approach for pain relief. By allowing adjustments to focus on either broad or specific pain areas, Spinal Modulation's technology aims to enhance patient comfort and reduce the adverse effects commonly associated with traditional spinal cord stimulators.

Nfocus Neuromedical, Inc. designs, develops, and markets endovascular neurosurgery solutions to cure intracranial aneurysms. The company offers revolutionary systems to treat neurovascular disease, including brain aneurysms. The company was formerly known as CardioVasc, Inc. and changed its name to Nfocus Neuromedical, Inc. in April 2007. The company was incorporated in 1997 and is based in Palo Alto, California. As of February 19, 2013, Nfocus Neuromedical, Inc. operates as a subsidiary of Covidien plc.

Action Pharma A/S is a biotechnology company focused on research and development, specializing in the discovery and development of novel drugs for cardiovascular, inflammatory, and metabolic diseases. Founded in 2000 and based in Holte, Denmark, the company aims to create treatment options for conditions such as type-II diabetes, obesity, kidney injury related to cardiac surgery, inflammatory bowel disease, rheumatoid arthritis, and inflammatory skin diseases like atopic dermatitis. Its product pipeline includes AP214, a modified MSH peptide analogue for post-surgical kidney injury; AP1030 and AP11 series, oral medications for type-II diabetes; AP1189, an anti-inflammatory compound for various inflammatory diseases; and AP405, another modified MSH peptide aimed at treating inflammatory skin conditions. Action Pharma's approach focuses on targeting melanocortin receptors, progressing its candidates toward clinical proof of concept to facilitate future partnerships.